Neuroprotective therapies: Preclinical reproducibility is only part of the problem

Science Translational Medicine

Volumn 7, Issue 299, 2015, Pages

  Tymianski, Michael ^a,b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; NA 1; NEUROPROTECTIVE AGENT; PLACEBO; POSTSYNAPTIC DENSITY PROTEIN 95 INHIBITOR; PROTEIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANALYTICAL ERROR; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; CLINICAL STUDY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; EMOTION; ENDOVASCULAR SURGERY; EXPLORATORY RESEARCH; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; MEDICAL INFORMATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; TARGET PRODUCT PROFILE; TRANSLATIONAL RESEARCH; TREATMENT FAILURE; TREATMENT OUTCOME; ANIMAL; PRECLINICAL STUDY; PROCEDURES; STANDARDS; STROKE;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; STROKE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84938702491     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac9412     Document Type: Article

References (10)

1. G. Llovera, K. Hofmann, S. Roth, A. Salas-Pérdomo, M. Ferrer-Ferrer, C. Perego, E. R. Zanier, U. Marmak, A. Rex, H. Party, V. Agin, C. Fauchon, C. Orset, B. Haelewyn, M.-G. De Simoni, U. Dirnagl, U. Grittner, A. M. Planas, N. Plesnila, D. Vivien, A. Liesz, Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia. Sci. Transl. Med. 7, 299ra121 (2015).
2. F. Prinz, T. Schlange, K. Asadullah, Believe it or not: How much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10, 712 (2011).
3. C. G. Begley, L. M. Ellis, Drug development: Raise standards for preclinical cancer research. Nature 483, 531-533 (2012).
4. S. C. Landis, S. G. Amara, K. Asadullah, C. P. Austin, R. Blumenstein, E. W. Bradley, R. G. Crystal, R. B. Darnell, R. J. Ferrante, H. Fillit, R. Finkelstein, M. Fisher, H. E. Gendelman, R. M. Golub, J. L. Goudreau, R. A. Gross, A. K. Gubitz, S. E. Hesterlee, D. W. Howells, J. Huguenard, K. Kelner, W. Koroshetz, D. Krainc, S. E. Lazic, M. S. Levine, M. R. Macleod, J. M. McCall, R. T. Moxley 3rd, K. Narasimhan, L. J. Noble, S. Perrin, J. D. Porter, O. Steward, E. Unger, U. Utz, S. D. Silberberg, A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187-191 (2012).
5. V. E. O?Collins, M. R. Macleod, G. A. Donnan, L. L. Horky, B. H. van der Worp, D. W. Howells, 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467-477 (2006).
6. S. T. Carmichael, Rodent models of focal stroke: Size, mechanism, and purpose. NeuroRx 2, 396-409 (2005).
7. M. Tymianski, Novel approaches to neuroprotection trials in acute ischemic stroke. Stroke 44, 2942-2950 (2013).
8. D. J. Cook, L. Teves, M. Tymianski, A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci. Transl. Med. 4, 154ra133 (2012).
9. M. D. Hill, R. H. Martin, D. Mikulis, J. H. Wong, F. L. Silver, K. G. Terbrugge, G. Milot, W. M. Clark, R. L. Macdonald, M. E. Kelly, M. Boulton, I. Fleetwood, C. McDougall, T. Gunnarsson, M. Chow, C. Lum, R. Dodd, J. Poublanc, T. Krings, A. M. Demchuk, M. Goyal, R. Anderson, J. Bishop, D. Garman, M. Tymianski, ENACT trial investigators, Safety and ef cacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 11, 942-950 (2012).
10. U.S. Department of Health and Human Services, FDA, Guidance for Industry and Review Staff. Target Product Profile-A Strategic Development Process Tool (2007); available at www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm080593.pdf